Directorio

If you choose to join this study, you or your child, will:

• Allow us access to your medical record for up to 5 years
• Answer questions about your health history and current symptoms
• Have a nasal swab
• Give a stool sample
• Complete 3 follow-up phone calls
• Have blood drawn (only if in the hospital or l)

We are doing this study to find out if pelvic floor physical therapy can improve sexual function for women who have undergone pelvic radiation.

We are doing this study to understand whether people who receive a lower radiation dose after an interim (the second scan) PET-CT identifies an early treatment response have a similar outcome to those receiving a standard radiation dose. The results of the interim PET-CT scan will be used to guide your radiation dose plan. Depending on the PET-CT results, you will either receive a reduced radiation dose or the standard radiation dose for your cancer.

Each person in the study will take part for about three and a half years. They will go to the clinic three times: the first time for the first shot, the second time six months later for the second shot, and the third time one month after the second shot to check safety. There will also be three phone calls to check on safety at 1 month, 12 months, and 18 months after the first shot. After that, people will visit the clinic once a year until the study ends.

We are doing this study to find the most effective, safe dose of an experimental drug called PF-0793440 (the study drug). We want to know how well it works on its own and in combination with other drugs for the treatment of different cancers in people who have KRAS mutation(s).

We are doing this study to find out if an experimental drug called navtemadlin (the study drug) is a safe and effective option for people with myelofibrosis (MF). We want to know how well it works when it is combined with ruxolitinib for people who did not get the desired results from ruxolitinib on its own.

We are doing this study to find the most effective, safe dose of an experimental drug called CLN-049 (the study drug) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).